Journal
Oncogene
Publication Date
10-1-2025
Volume
44
Issue
39
First Page
3641
Last Page
3651
Document Type
Open Access Publication
DOI
10.1038/s41388-025-03560-4
Rights and Permissions
Panda, H., Rowland, N.G., Krall, C.M. et al. NRF2 immunobiology in cancer: implications for immunotherapy and therapeutic targeting. Oncogene 44, 3641–3651 (2025). https://doi.org/10.1038/s41388-025-03560-4 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Recommended Citation
Panda, Harit; Rowland, Natalie G; Krall, Caroline M; Bowman, Brittany M; Major, Michael B; and Zolkind, Paul, "NRF2 immunobiology in cancer: Implications for immunotherapy and therapeutic targeting." Oncogene. 44, 39. 3641 - 3651. (2025).
https://digitalcommons.wustl.edu/oa_4/5967
Department
ICTS (Institute of Clinical and Translational Sciences)
